Olaparib Monotherapy Yields Good PSA Response Rates in Prostate Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 26, 2024 -- For men with high-risk biochemically recurrent prostate cancer, olaparib monotherapy yields good prostate-specific antigen (PSA) response rates, especially among those with BRCA2, according to a study published online Aug. 22 in JAMA Oncology.
Catherine H. Marshall, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined the activity of olaparib monotherapy among patients with high-risk biochemically recurrent prostate cancer after radical prostatectomy in a phase 2, single-arm nonrandomized controlled trial. A total of 51 male patients were enrolled and received treatment with olaparib twice daily until doubling of baseline PSA, clinical or radiographic progression, or unacceptable side effects.
The researchers found 13 participants (26 percent) had a 50 percent or higher decline in PSA from baseline (PSA50); all were within the homologous recombination repair-positive group (13 of 27; 48 percent). A PSA50 response occurred in all 11 participants with BRCA2 alterations. Fatigue, nausea, and leukopenia were common adverse events (63, 55, and 43 percent, respectively), which were consistent with known adverse effects of olaparib.
"Molecularly targeted therapies in select patient populations may be a reasonable treatment strategy for some patients with recurrent prostate cancer, even in the absence of androgen deprivation therapy," the authors write.
Several authors disclosed ties to pharmaceutical companies, including AstraZeneca, which provided olaparib and financial support for the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Mental Health Utilization Increased Around Time of Prostate Cancer Diagnosis
FRIDAY, Aug. 16, 2024 -- There is an increase in psychotropic medication use and mental health service use around the time of prostate cancer diagnosis, according to a study...
Baseline MRI PI-RADS Linked to Biopsy Reclassification in Prostate Cancer
WEDNESDAY, Aug. 14, 2024 -- The baseline magnetic resonance imaging (MRI) Prostate Imaging Reporting and Data System (PI-RADS) score is associated with biopsy reclassification...
Mortality Risk High for Some Gleason Grade 1 Prostate Cancer Patients
THURSDAY, Aug. 1, 2024 -- For patients with Gleason Grade Group (GGG) 1 prostate cancer (PC), those with percentage positive biopsies (PPB) >50 percent or prostate-specific...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.